Where Are Checkpoint Inhibitors Standard of Care for NSCLC? Where Are Checkpoint Inhibitors Standard of Care for NSCLC?

Dr Mark Kris discusses the use of checkpoint inhibitors in the adjuvant and neoadjuvant settings for patients with non-small cell lung cancer.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news